Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
04/2005
04/19/2005US6881419 Vitamin formulation for enhancing bone strength
04/19/2005US6881415 Emulsifier-free finely dispersed water-in-oil type systems
04/19/2005US6881410 Treatment of E. faecium infection
04/19/2005US6881409 Compositions and methods for promoting nerve regeneration
04/19/2005US6881406 Administering an effective amount of a Chemokine receptor (CCR4) modulating agent, in a dose effective to modulate trafficking of systemic memmory T cells
04/19/2005US6881395 Ligand for use as tool in the treatment of tumors in humans
04/19/2005CA2315189C Integrin receptor antagonists
04/16/2005CA2480199A1 Fp-ghrelin
04/14/2005WO2005033700A1 Method of screening insulin resistance-improving agent
04/14/2005WO2005033301A1 Cell activation method and cell production method and medicinal composition using the same
04/14/2005WO2005033272A2 In vivo synthesis of connective tissues
04/14/2005WO2005032592A1 Hypnotic composition
04/14/2005WO2005032590A1 Remedy for diabetes
04/14/2005WO2005032589A1 Prevention and treatment for gvhd
04/14/2005WO2005032588A1 Preparation containing basic drug
04/14/2005WO2005032567A2 Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium
04/14/2005WO2005032562A1 Methods for treating acute and overuse sprain and strain using hyaluronic acid
04/14/2005WO2005032561A1 INVENTION RELATING TO FUNCTION OF HIV-Vpr
04/14/2005WO2005032556A1 Method for reducing pain
04/14/2005WO2005032552A1 Hypnotic composition
04/14/2005WO2005032546A1 Hypnotic composition
04/14/2005WO2005032545A1 Composition for treating inflammatory bowel disease
04/14/2005WO2005032543A1 Hypnotic composition
04/14/2005WO2005032535A1 Nerve regeneration promoters
04/14/2005WO2005032532A1 Antimycotic composition
04/14/2005WO2005032530A1 Pharmaceutical composition for external application
04/14/2005WO2005032529A1 Mycocide composition
04/14/2005WO2005032522A1 Topical aerosol foams
04/14/2005WO2005032521A2 Non-flammable topical anesthetic liquid aerosols
04/14/2005WO2005032515A1 New use, pharmaceutical preparations as well as a process for their production
04/14/2005WO2005032480A2 Methods, compositions,, apparatuses containing tetrameric oxygen
04/14/2005WO2005032478A2 Treatment for diabetic microvascular and macrovascular complications
04/14/2005WO2005032477A2 Gamma-tocopherol treatment for cystic fibrosis
04/14/2005WO2005032462A2 Glucocerebroside treatment of disease
04/14/2005WO2005032456A2 Tricalcium phosphates, their composites, implants incorporating them, and methods for their production
04/14/2005WO2005032387A2 Apparatus and method for administering a therapeutic agent
04/14/2005WO2005021038A3 Agent for treating metabolic syndrome
04/14/2005WO2005011734A3 Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
04/14/2005WO2005009336A9 Antibacterial methods and compositions
04/14/2005WO2005007174A3 Synergistic antimicrobial ophthalmic combination
04/14/2005WO2005000318A3 Method of inducing apoptosis and inhibiting cardiolipin synthesis
04/14/2005WO2004096216A3 Use of a topical medicament comprising riluzole
04/14/2005WO2004092215A3 Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin-2
04/14/2005WO2003073983A3 Methods and compositions in treating pain using diacylglycerol kinase epsilon
04/14/2005WO2003070971A3 Modulators of paraptosis and related methods
04/14/2005WO2003063573A3 Method for treating diseases with omega interferon
04/14/2005WO2003051287A3 Topical compositions and methods for treatment of adverse effects of ionizing radiation
04/14/2005WO2003027228A3 Receptors and membrane-associated proteins
04/14/2005US20050080468 Methods and apparatus for treating diseased tissue
04/14/2005US20050080140 Administering peroxisome proliferator-activated receptor (PPAR) delta agonist; a prostacyclin synthase gene or a protein encoded by the gene; rheumatoid arthritis, osteoarthritis, Crohn's disease, Guillain-Barre syndrome, skin disorders, post by-pass surgery restenosis, transplantation rejection
04/14/2005US20050080122 Anti-viral compounds
04/14/2005US20050080109 Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis
04/14/2005US20050080099 Methods and kits for treating depression or preventing deterioration of cognitive function
04/14/2005US20050080083 Compositions of a cyclooxygenase-2 selective inhibitor and an angiotensin II receptor antagonist for the treatment of central nervous system damage
04/14/2005US20050080071 Treatment methods
04/14/2005US20050080062 preventing or delaying the progression of hormone receptor breast cancer following estrogen antagonist therapy by subsequent therapy with an estrogen depleting agent prior to disease progression
04/14/2005US20050080061 inhibit the binding of cortisol to its receptors; Mifepristone; dexamethasone and betamethasone
04/14/2005US20050080056 Alpha 1 antagonist; reduces pupil size in dim light, but less reduction in pupil size in bright light; artificial tear; tamsulosin, urapidil
04/14/2005US20050080052 Fine dry powder; rapidly spreads and melts over lung and air passageway surfaces
04/14/2005US20050080045 topical administration; prevention of STDs preferably a viral disease other than HIV, e.g. HPV or genital herpes and especially acyclovir resistant genital herpes
04/14/2005US20050080041 Method and composition for the treatment of adenoviral ocular infections
04/14/2005US20050080037 Methods for treating acute and overuse sprain and strain using hyaluronic acid
04/14/2005US20050080035 Use of BVDU for inhibiting the growth of hyperproliferative cells
04/14/2005US20050080034 Beta-L-2'-deoxynucleosides for the treatment of resistant HBV strains and combination therapies
04/14/2005US20050080031 Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
04/14/2005US20050080029 Administering to the cell the compound to be delivered, an organic halide, and/or a carrier; ultrasound may also be applied
04/14/2005US20050080010 Suppression of immune response via inhibition of cathepsin S
04/14/2005US20050080006 Apo2L/TRAIL formulations including lyophilized and crystal compositions; may be used in inducing apoptosis in mammalian cells including cancer cells by exposing mammalian cells to an effective amount of an Apo-2 ligand formulation described herein
04/14/2005US20050079575 Human receptor molecules
04/14/2005US20050079572 Expression vector comprising nuclelotide sequences coding brain acid soluble protein 1 (BASP1) for use in prevention and treatment of infection, cell proliferative, inflammatory and autoimmune disorders; gene therapy; immunotherapeutics
04/14/2005US20050079538 polynucleotides which identify and encode human secreted proteins (SECP); expression vectors, host cells, antibodies, agonists, and antagonists; drug screening; anticarcinogenic agents
04/14/2005US20050079235 Using green tea extract
04/14/2005US20050079233 Using plant extracts
04/14/2005US20050079221 Ibuprofen narcotic composition and method for making same
04/14/2005US20050079209 Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds
04/14/2005US20050079176 Treating stress response with chemokine receptor ccr5 modulators
04/14/2005US20050079164 Solubilized CoQ-10 and carnitine
04/14/2005US20050079161 Transluminal application of adult stem cells for body organ tissue repair
04/14/2005US20050079159 Autologous tissue for connecting structures; regeneration of tissue; cell differentiation of pluripotent cells
04/14/2005US20050079157 Combination bacteriolytic therapy for the treatment of tumors
04/14/2005US20050079156 Method of treating endometreosis
04/14/2005DE10343365A1 Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation Pharmaceutical formulations of xanthates and inhibitors of viral nucleic acid replication
04/14/2005CA2581940A1 Methods, compositions,, apparatuses containing tetrameric oxygen
04/14/2005CA2540895A1 Combinations of ziconotide and opioids for reducing pain
04/14/2005CA2540741A1 Agent for treating diabetes
04/14/2005CA2540666A1 Glucocerebroside treatment of disease
04/14/2005CA2540537A1 New use, pharmaceutical preparations as well as a process for their production
04/14/2005CA2539025A1 Composition for treating inflammatory bowel disease
04/14/2005CA2539010A1 Gamma-tocopherol treatment for cystic fibrosis
04/14/2005CA2537769A1 Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium
04/14/2005CA2535085A1 Tricalcium phosphates, their composites, implants incorporating them, and methods for their production
04/13/2005EP1522584A2 Phosphatidylinositol 3-kinase p110 delta catalytic subunit
04/13/2005EP1522313A1 Combination therapy of radiation and valdecoxib for the treatment of neoplasia
04/13/2005EP1522310A1 Therapeutic uses of dunaliella powder
04/13/2005EP1522306A1 A pharmaceutical product for hormone replacement therapy comprising tibolone or a derivative thereof and estradiol or a derivative thereof
04/13/2005EP1522305A1 Combinations of sumatriptan with a cyclooxygenase II inhibitor
04/13/2005EP1521847A2 Marker genes for determining renal toxicity
04/13/2005EP1521845A1 Method for detecting increased susceptibility to tumours
04/13/2005EP1521832A2 Genes
04/13/2005EP1521824A2 Nucleic acid-associated proteins
1 ... 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 ... 1151